

61  
BAKER BOTTS LLP



RECEIVED  
DEC 15 2003  
TECH CENTER 1200/1000  
+  
1200/1000

REQUEST  
FOR  
**CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000,  
provides for continued examination of an utility or plant application  
filed on or after June 8, 1995.  
See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/910,186
Filing Date	July 20, 2001
First Named Inventor	Leonard Smith et al.
Group Art Unit	1645
Examiner Name	Portner, VA
Attorney Docket Number	A33626A 067252.0107

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a.  Previously submitted  
i.  Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).  
ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_  
iii.  Other \_\_\_\_\_
- b.  Enclosed  
i.  Amendment/Reply  
ii.  Affidavit(s)/Declaration(s)  
iii.  Information Disclosure Statement (IDS)  
iv.  Other \_\_\_\_\_

2. Miscellaneous

- a.  Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)  
b.  Other \_\_\_\_\_

3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 02-4377  
i.  RCE fee required under 37 C.F.R. § 1.17(e)  
ii.  Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)  
iii.  Other Any additional charges under 37 CFR 1.16 and 1.117
- b.  Check in the amount of \$ 1720 enclosed  
c.  Payment by credit card (Form PTO-2038 enclosed)


**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Carmella L. Stephens	Registration No. (Attorney/Agent)	41,328
Signature	<i>Carmella L. Stephens</i>	Date	December 3, 2003

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Alexandria, VA 22313-1450, or facsimile transmitted to the US Patent and Trademark Office on:

Name (Print/Type)	Carmella L. Stephens
Signature	<i>Carmella L. Stephens</i>



**BAKER BOTTS LLP**

Attorney Docket Number: A33626A 067252.0107

Title: RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN

Use Space Below for Additional Information:

This submission includes:  
RCE Transmittal (2 sheets);  
Petition for Extension of Time (2 sheets);  
Fee Transmittal (1 sheet in duplicate);  
Amendment (26 sheets);  
Two Exhibits (27 sheets);  
Terminal Disclaimer (3 sheets);  
Sequence Listing in paper form (46 sheets);  
Sequence Listing in CRF (1 diskette);  
Assignment (6 sheets);  
BB Check # 173288; and  
Return Postcard.